Secondary metabolites, 3D structure: Trivial name – terretonin

Date: 26 November 2013

  • Terretoninweb3D

Prev
Next

Secondary metabolites, 3D structure: Trivial name – terretonin

Copyright: n/a

Notes:

Species: A. terreusMolecular formulae: C26H3209Selected references: McIntyre, C.R.; Scott, F.E.; Simpson, T.J.; Trimble, L.A. and Vederas, J.C., Application of Stable Isotope Labelling Methodology to the Biosynthesis of the Mycotoxin, Terretonin, by Aspergillus terreus: Incorporation of 13C Labelled Acetates and Methionine, 2H and 13C, 18O Labelled Ethyl 3,5-Dimethylorsellinate and Oxygen-18 Tetrahedron 1989 45 () 2307-2321 J. P. Springer, J. W. Dorner, R. J. Cole, R. H. Cox Terretonin, a Toxic Compound from Aspergillus terreus J. Org. Chem. 1979 44 () 4852-4854

Images library

Showing 10 posts of 2574 posts found.

  • Title

    Legend

  • Haemofungin

    haemofungin

  • E1210 structure

    E1210

  • ABPA and mucoid impaction

    Patient YML ABPA and mucoid impaction Image 1, Patient YML ABPA and mucoid impaction Image 2

  • Patient JSG: Nicotine stained fingers in ABPA with bronchiectasis

    Patient with chronic productive cough, chest pain and ABPA, unable to take itraconazole or nebulised amphotericin B. Smokes at least 40 roll up cigarettes a day.

    Nicotine stained fingers - image 1, Nicotine stained fingers - image 2

  • T-2307

    The chemical structure of the novel arylamidine T-2307

    T2307

  • Laryngeal Aspergillosis, ptSA

    Laryngeal aspergillosis, probably related to inhaled corticosteroids.

    Image A., Image B., Image C., Image D.

  • VL-2397 (ASP2397)

    VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two posters at the 2014 ICAAC meeting which described the in vitro and the in vivo antifungal activities of this drug. The differentiating attributes from the preclinical data of VL-2397 include:

    • A novel mechanism of action, with a potential to be complementary or synergistic with the existing classes of antifungals.
    • Rapid fungal cell kill activity demonstrated in preclinical models, which was faster than marketed antifungals.
    • Activity against azole-resistant fungal species.
    • Low propensity for P450 drug-drug interactions.

    VL-2397 (ASP2397)

  • SCY-078 (MK-3118)

    SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor, Formely MK-3118.

    SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor

  • Biafungin acetate

    Biafungin acetate, a new echinocandin

    Biafungin acetate, a new echinocandin

  • Primary Aspergillus pneumonia

    Pt DSM Community acquired primary Aspergillus pneumonia. Two x-rays taken on 02/02/2010 then 05/03/2010

    Pt DSM, Community acquired Aspergillus pneumonia 02/02/2010, Pt DSM, Community acquired Aspergillus pneumonia 02/02/2010